This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Google Scholar Articles by Belvisi, M. G. Articles by Hele, D. J. PubMed PubMed Citation Articles by Belvisi, M. G. Articles by Hele, D. J. Related Content Translating Basic Research into Clinical Practice

Peroxisome Proliferator-Activated Receptors as Novel Targets in Lung Disease^*

^* From the Respiratory Pharmacology Group, Airway Diseases Section, National Heart & Lung Institute, Faculty of Medicine, Imperial College, London, UK.

Correspondence to: Maria Belvisi, PhD, National Heart & Lung Institute, Imperial College, Respiratory Pharmacology, Guy Scadding Building, Dovehouse St, London SW3 6LY, UK; e-mail: m.belvisi{at}imperial.ac.uk

Abstract

Inflammatory diseases of the lung such as asthma and COPD represent a major worldwide health problem. There are potent antiinflammatory drugs available to treat asthma, such as the glucocorticoids, but these produce unwanted side effects and exhibit limited efficacy in the treatment of COPD. The identification of the peroxisome proliferator-activated receptors (PPARs) PPAR, PPAR, and PPAR opened up a new avenue of research as it was discovered that they exhibited antiinflammatory and immunomodulatory properties. In animal models of allergic and occupational asthma, COPD and pulmonary fibrosis PPARs are involved in the inflammatory cascade, and treatment with PPAR agonists reduces inflammation and results in beneficial outcomes. The actions of PPAR and PPAR activation are thought to be due to their ability to down-regulate proinflammatory gene expression and inflammatory cell functions, and as such makes them an attractive target for novel drug intervention. PPAR has been shown to be involved in wound healing, and its activation may enhance the effects of PPAR agonists. The only fly in the ointment is the observation of an increased incidence of cardiovascular events in diabetic patients treated with the PPAR agonist rosiglitazone. However, a clinical trial is underway to examine the effect of rosiglitazone in asthma patients, and the outcome of this trial is awaited with much anticipation. PPARs are novel targets for lung disease, and the continued work with PPAR agonists may result in a potential new treatment for these chronic inflammatory lung diseases.

Key Words: asthma • COPD • inflammation • novel target • peroxisome proliferator-activated receptor